Retaspimycin

Drug Profile

Retaspimycin

Alternative Names: IPI-504; MEDI-561; Retaspimycin hydrochloride

Latest Information Update: 10 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Infinity Pharmaceuticals
  • Developer Dana-Farber Cancer Institute; Infinity Pharmaceuticals; Massachusetts General Hospital
  • Class Antineoplastics; Benzoquinones; Macrocyclic lactams; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Gastrointestinal stromal tumours
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Breast cancer; Gastrointestinal stromal tumours; Multiple myeloma; Non-small cell lung cancer; Prostate cancer

Most Recent Events

  • 15 Dec 2016 Biomarkers information updated
  • 01 Oct 2014 Infinity Pharmaceuticals completes a phase I/II trial in Non-small cell lung cancer with KRAS mutation (combination therapy, second-line therapy) in USA (NCT01427946)
  • 01 Apr 2014 Infinity Pharmaceuticals completes a phase II trial in Non-small cell lung cancer in Taiwan, Russia, Romania, South Korea, Hungary and USA (NCT01362400)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top